Status:
UNKNOWN
Host DNA Methylation for Endometrial Cancer Screening
Lead Sponsor:
Lei Li
Collaborating Sponsors:
Beijing Qiyuanjuhe Biotechnology Co., Ltd
Conditions:
Cancer Screening
Endometrial Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening in a multi-center cohort. Th...
Eligibility Criteria
Inclusion
- With uterine and uterine cervix intact
- Aged 18 years or older
- With accessible histological results of endometrium
- Signed an approved informed consents
- With accessible cervical cytology before harvesting endometrial histology
Exclusion
- Not meeting all of the inclusion criteria
Key Trial Info
Start Date :
March 13 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 13 2022
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT05290415
Start Date
March 13 2022
End Date
September 13 2022
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730